论文部分内容阅读
本文应用超滤法测定血清中游离苯妥英浓度的方法,并采用荧光酶免疫法对患者的血清、血清超滤液、唾液、脑脊液进行苯妥英浓度测定,研究它们的相关性。通过测定6名癫痫患者单剂量口服苯妥英钠后血清、血清超滤液、唾液中的药物浓度,计算其动力学参数。实验结果表明,血清超滤液、唾液、脑脊液中苯妥英浓度分别为血清药物浓度的11%、10%、11%,有良好的相关性。各样品测得的动力学数据基本一致,药物浓度—时间曲线变化相同。血清超滤液、唾液、脑脊液样品中苯妥英浓度均反映了患者体内游离药物浓度的情况,唾液样品收集方便、迅速,对患者无损伤,适用于临床进行治疗药物监测。
In this paper, ultrafiltration method for the determination of serum free phenytoin concentration, and the use of fluorescence enzyme immunoassay of patients with serum, serum ultrafiltrate, saliva, cerebrospinal fluid of phenytoin concentrations were measured to study their relevance. The kinetic parameters of six epilepsy patients were determined by measuring the concentration of the drug in the single oral dose of phenytoin, serum ultrafiltrate and saliva. The experimental results show that the concentrations of phenytoin in serum ultrafiltrate, saliva and cerebrospinal fluid are respectively 11%, 10% and 11% of serum drug concentration, and have a good correlation. The kinetic data of each sample were basically the same, and the drug concentration-time curve changed the same. The concentrations of phenytoin in the serum ultrafiltrate, saliva and cerebrospinal fluid samples all reflect the concentration of the free drug in the patient’s body. Saliva sample collection is convenient and rapid, and has no damage to the patient and is suitable for the clinical monitoring of therapeutic drugs.